Clinical OMICS

MAY-JUN 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 9 of 51

8 Clinical OMICs May/June 2018 News help with this as it offers scale, effi- ciency, and data-analysis capabilities researchers need to manage and ana- lyze massive datasets. By augmenting researchers, it in turn helps institutes and organizations advance their work all while meeting stringent data use, security, and privacy requirements." DNAnexus, another genomics heavyweight, has created the global network for genomic and biomedi- cal data, operating in North Amer- ica, Europe, Asia-Pacific (including China), South America, and Africa. In 2015, DNAnexus was awarded a research and development contract by the FDA's Office of Health Informatics to build precisionFDA, an open source platform for community sharing of genomic information. DNAnexus also provided the platform for the Regen- eron Genetics Center. "The whole point of the [genomic] analytics is to take these mon- strously huge files and make them into something useable," said Rich- ard Daly, CEO of DNAnexus. "What makes genomics data useful is to mix genomic and phenotypic data. This can only really be done on the cloud right now." According to Daly, the ability to operate on the cloud with more and larger datasets helps to increase research insights and provide more opportunities for cures. "The amazing thing, the most nota- ble thing" is the truly visionary work of St. Jude, which offers care to chil- dren for free, along with its "incredi- ble research," Daly noted. "You can't visit St. Jude without getting recruited to their mission. We're really excited to be a part of this, not because it's an important technological advancement, but you have to love the mission. This is special." Daly is particularly impressed that St. Jude is making its data freely available to further cancer research. "This is unique," he said. About 7,500 patients are seen at Nashville, Tenn.-based St. Jude annu- ally, with most of them treated on a continuing outpatient basis, and they are part of ongoing research pro- grams, according to the hospital. St. Jude has treated children from all 50 states and from around the world. Patients at St. Jude are referred by a physician, and nearly all have a dis- ease currently under study and are eligible for a clinical trial. (continued from previous page) Richard Williams Leaves GRAIL to Head Oncology Program at WuXi NextCODE Genomic data company WuXi NextCODE has announced the appointment of Richard Williams, M.D., as managing director and head of oncology programs to lead contin- ued development of the company's cancer business. Williams served most recently at Illumina spin-out GRAIL as program lead and lead medical director for the Circulating Cell-Free Genome Atlas (CCGA) program. At WuXi NextCODE, Williams will oversee the company's cancer business, including working on the company's SeqPlus service that promises to significantly improve se- quencing and data generation from FFPE samples, and creating massively scalable and instantly queriable databases of tumor and patient sequence and phenotypic data. His work will also incorporate AI and deep learning to gain novel insights into cancer initia- tion, development, and therapeutic sensitivity and resistance. n St. Jude Children's Research Hospital is making its pediatric cancer genomic data freely available via St. Jude Cloud with the hope of significantly accelerating pediatric cancer research. studiogstock / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAY-JUN 2018